GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Change In Inventory

KNSA (Kiniksa Pharmaceuticals International) Change In Inventory : $5.2 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International Change In Inventory?

Kiniksa Pharmaceuticals International's change in inventory for the quarter that ended in Mar. 2025 was $4.3 Mil. It means Kiniksa Pharmaceuticals International's inventory declined by $4.3 Mil from Dec. 2024 to Mar. 2025 .

Kiniksa Pharmaceuticals International's change in inventory for the fiscal year that ended in Dec. 2024 was $4.8 Mil. It means Kiniksa Pharmaceuticals International's inventory declined by $4.8 Mil from Dec. 2023 to Dec. 2024 .

Kiniksa Pharmaceuticals International's Total Inventories for the quarter that ended in Mar. 2025 was $22.1 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Kiniksa Pharmaceuticals International's Days Inventory for the quarter that ended in Mar. 2025 was 35.84.

Inventory Turnover measures how fast the company turns over its inventory within a year. Kiniksa Pharmaceuticals International's Inventory Turnover for the quarter that ended in Mar. 2025 was 2.55.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Kiniksa Pharmaceuticals International's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.18.

Kiniksa Pharmaceuticals International Change In Inventory Historical Data

The historical data trend for Kiniksa Pharmaceuticals International's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals International Change In Inventory Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Inventory
Get a 7-Day Free Trial Premium Member Only - -3.68 -17.92 -9.52 4.76

Kiniksa Pharmaceuticals International Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.84 -7.58 6.18 2.32 4.30

Kiniksa Pharmaceuticals International Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International  (NAS:KNSA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kiniksa Pharmaceuticals International's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=24.2165/61.658*365 / 4
=35.84

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kiniksa Pharmaceuticals International's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=61.658 / 24.2165
=2.55

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kiniksa Pharmaceuticals International's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=24.2165 / 137.785
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Change In Inventory Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Change In Inventory
Comparable Companies
ANIP BGM NDOI BCRX DVAX SUPN PCRX AMPH HROW COLL ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ
Website
https://www.kiniksa.com
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Executives
Eben Tessari officer: Chief Business Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa officer: Interim CFO C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Michael R Megna officer: Chief Accounting Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
Sanj K Patel director, 10 percent owner, officer: Chairman & CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat officer: Group VP & Rilonacept GM C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini officer: Chief Medical Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart director C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano officer: Chief Clinical Dev. Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham 10 percent owner, officer: Chief Legal Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063